Nicotinamide (vitamin B3) treatment improves response to G‐CSF in severe congenital neutropenia patients

医学 中性粒细胞减少症 粒细胞 先天性中性粒细胞减少 粒细胞集落刺激因子 败血症 内科学 髓样 胃肠病学 烟酰胺 免疫学 化疗 生物 酶 生物化学
作者
Е. А. Деордиева,O. A. Shvetz,K. A. Voronin,Alexei Maschan,Karl Welte,Julia Skokowa,G. А. Novichkova,Anna Shcherbina
出处
期刊:British Journal of Haematology [Wiley]
卷期号:192 (4): 788-792 被引量:15
标识
DOI:10.1111/bjh.17313
摘要

Severe congenital neutropenia (CN) is an inherited bone marrow failure syndrome with markedly reduced granulocyte number and function that often manifests with life-threatening bacterial infections.1 Granulocyte colony-stimulating factor (G-CSF) treatment is the primary therapeutic approach and is aimed at keeping granulocyte levels at or above 1 000/µl to prevent infectious complications.2 Some CN patients require high doses of G-CSF to reach this goal, and a small group of patients is not responsive to G-CSF therapy at all. Overall the cumulative 15-year incidence of death from sepsis for CN patients was described to be as high as 10%.3 There is also some evidence that the cumulative risk of development of acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) is higher in patients who require higher doses of G-CSF.3, 4 The association of G-CSF dose with the relative hazard of MDS/AML or sepsis death was also detected.3 Therefore, other therapeutic options that may lead to a reduction of G-CSF dose and increase in granulocyte functions are required. We recently demonstrated that nicotinamide (NA, vitamin B3) acts through the NAD+/SIRT1 protein deacetylation pathway, leading to an upregulating of the expression of G-CSF and G-CSF receptors.5 When we treated healthy volunteers with 20 mg/kg/day of nicotinamide (NA, Jenapharm, Jena, Germany) daily, they showed a marked increase in neutrophilic granulocyte numbers.5 Therefore, we aimed to evaluate whether the NA treatment of CN patients will increase neutrophil numbers and may lead to a reduction of the required therapeutic G-CSF dose. For this, CN patients were orally treated with 20 mg/kg/day of NA in addition to G-CSF therapy. After three months of treatment, absolute numbers of peripheral blood neutrophils, monocytes, eosinophils, thrombocytes, and lymphocytes, as well as haemoglobin, were evaluated. In some patients, blood and bone marrow counts were evaluated after one year on NA therapy. Eighteen patients were included in the study: 15 CN patients and three patients with cyclic neutropenia (CyN) (Table I). The study included 11 males and seven females at ages of 0·5 to 31 years [median 5·5 years; first quartile (Q1) 3·6, third quartile (Q3) 8·5]. The diagnosis of CN or CyN was made based on Severe Chronic Neutropenia International Registry (SCNIR) diagnostic criteria.1 Fourteen CN patients harboured mutations of ELANE, two patients had X-linked CN harbouring WAS mutations, and in two patients, no genetic defect has been detected yet. Two CyN patients harboured ELANE mutations, and in one CyN patient no mutations were detected despite clear cycling of the neutrophil counts (Table I). All patients received G-CSF in doses between 0·6 and 50·8 µg/kg/day before initiation of NA therapy. The local ethic committees approved the study protocol, the patients and\or their parents gave informed consent to participate in the study. Analysis of blood counts after three months of NA treatment revealed a gradual increase of absolute neutrophil counts (ANC) in 14 of 18 patients (78%). In one of them G-CSF was completely replaced by NA treatment (Table I). In patients on combined G-CSF and NA therapy (including mono-NA therapy), median ANC before NA was 0·95 × 109/l (Q1 0·64, Q3 1·51) and in combination with NA was 1·80 × 109/l (Q1 1·50, Q3 2·73) (Fig 1A, B), and the median increase in ANC was 0·76 × 109/l (Q1 0·64, Q3 1·4l; P < 0·001). No statistically significant differences in other blood cell counts were detected in the subsample of 16 patients for whom complete blood counts were available (Fig 1C). In nine out of 18 patients (50%), the addition of NA led to a reduction of the G-CSF dose required to reach ANCs above 1 000/µl including complete replacement of G-CSF by NA in one patient. Thus, median G-CSF dose in 18 patients was reduced from 13·3 µg/kg/day (Q1 4·4, Q3 23·8) before NA to 8·6 µg/kg/day (Q1 1·6, Q3 15·1) after three months of treatment, with a median decrease of G-CSF dose of 0·8 µg/kg/day (Q1 0, Q3 3·3; P = 0·007; Fig 1D). The beneficial effect of NA and G-CSF therapy was observed in most patients during one year of continuous treatment; one patient was lost to follow-up. After one year of observations, ANC was 1·66 × 109/l (Q1 1·00, Q3 2·85), and the median increase of ANC since the start of therapy was 0·85 × 109/l (Q1 0·08, Q3 1·57; P = 0·004). NA was well-tolerated as a long-term treatment option, without severe adverse events. Four patients have currently been treated with NA for more than five years and six patients for more than three years without exhaustion of responses to NA. During the time on combinatorial treatment with NA and G-CSF, three patients received bone marrow transplantation due to the acquisition of monosomy 7 (pt. # 5 two years, pt. #7 1·5 years and pt. # 12 five years after initiation of NA treatment). Two of these patients harboured ELANE mutations (Cys151Ser in pt. #7 and Gly214Arg on pt. #12) that are associated with high risk of AML or MDS.6 Morphological analysis in the remaining patients revealed no obvious differences in the bone marrow morphology (data not shown). We also observed a reduction of the frequency and severity of bacterial infections. As an example, one CN patient (#7) required G-CSF doses up to 50 µg/kg/day to achieve neutrophil counts above 1 000/µl. Upon addition of NA, neutrophil counts of more than 3 000/µl were achieved without further increases of the G-CSF dose. Upon continuous treatment (three months) of this patient, we were able to decrease the G-CSF dose to 12·5 µg/kg/day, with good clinical and laboratory results (Figure S1A). In one CyN patient (#18), monotherapy with nicotinamide was even sufficient to prevent infections, despite continuous cycling. This patient was treated with 5 mg/kg/day of NA for more than two years. Another CyN patient (#2) had episodes of profound neutropenia with absent neutrophils and complete unresponsiveness to G-CSF, during which he developed multiple severe infections. Upon the addition of NA, the nadir of his granulocyte level increased to above 0·40 × 109/l, with a reduction in the number of infections. Taken together, in our group of CN and CyN patients, NA treatment led to an increase of neutrophil counts and a decrease of required G-CSF doses with continuous clinical and laboratory responses. Therefore, the use of NA in combination with a reduced dose of G-CSF for the treatment of CN and CyN patients is promising and should be further investigated in a larger cohort of patients. It would be interesting to investigate whether patients with other types of inherited or acquired neutropenia will respond to NA. Particularly, implementation of NA in the treatment of chemotherapy-induced neutropenia may shorten neutropenic phases, improving chemotherapy regimens. It would also be important to investigate whether decreasing the dose of G-CSF will lead to reduced acquisition of G-CSFR mutations, a risk factor for the development of leukaemias. In three CN patients on combinatorial NA and G-CSF therapy, we observed acquisition of monosomy 7. These data suggest that reduction of the G-CSF dose may not prevent leukaemogenic transformation. However, whether NA protects from the acquisition of leukaemia-associated CSF3R and/or RUNX1 mutations or prevents leukaemogenesis has to be further investigated in a long-term observation study of a larger group of patients. Also, analysis of the granulocyte functions of NA-treated patients may further strengthen our observation of reduced frequency and severity of bacterial infections in these patients upon NA therapy. This work was supported by the BMBF (JS, KW). The authors have no relevant conflicts of interest to disclose. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被叫你吃布丁采纳,获得10
刚刚
1秒前
树枝完成签到 ,获得积分10
2秒前
牧百川发布了新的文献求助10
2秒前
机灵的胡萝卜完成签到,获得积分10
2秒前
2秒前
斯文败类的应助被nhzz2023采纳,获得20
3秒前
111完成签到,获得积分10
3秒前
郑睿涛发布了新的文献求助10
3秒前
思源的应助被幸福采纳,获得10
3秒前
医路成功完成签到,获得积分10
5秒前
花生仔发布了新的文献求助10
6秒前
共享精神的应助被木子采纳,获得10
7秒前
tourist585发布了新的文献求助10
8秒前
大胆妖孽完成签到,获得积分10
9秒前
小蘑菇的应助被优美梦秋采纳,获得10
10秒前
10秒前
10秒前
zhaoben发布了新的文献求助10
10秒前
TaoJ举报小唐的求助涉嫌违规
10秒前
11秒前
桐桐的应助被叫你吃布丁采纳,获得10
13秒前
15秒前
wwwww发布了新的文献求助10
15秒前
Akim的应助被huoyunli采纳,获得30
15秒前
16秒前
16秒前
Maestro_S的应助被许右采纳,获得10
16秒前
Ren的应助被daomaihu采纳,获得100
16秒前
Ren的应助被daomaihu采纳,获得100
17秒前
Ren的应助被daomaihu采纳,获得100
17秒前
DW的应助被小SCI采纳,获得10
17秒前
烟花的应助被板凳饭团采纳,获得10
18秒前
alex发布了新的文献求助30
20秒前
阳利发布了新的文献求助10
20秒前
郑睿涛发布了新的文献求助10
21秒前
PMY完成签到,获得积分10
21秒前
Orange的应助被章鱼采纳,获得10
21秒前
22秒前
贪玩果汁发布了新的文献求助10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183730
求助须知:如何正确求助?哪些是违规求助? 9572975
关于积分的说明 21828453
捐赠科研通 7780887
什么是DOI,文献DOI怎么找? 3434086
关于科研通互助平台的介绍 2558276
邀请新用户注册赠送积分活动 2480557